Seamus Cotter
Seamus Cotter has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Jacob
Department of General Practice RCSI University of Medicine and Health Sciences Dublin Ireland
7 shared publications Alan Smith
HSE, National Screening Service, Dublin, Ireland
6 shared publications- Frank Doyle
RCSI University of Medicine and Health Sciences, Dublin, Ireland
5 shared publications Patrick Redmond
Dept. of General Practice, RCSI University of Medicine and Health Sciences, Dublin, Leinster
5 shared publicationsJarushka Naidoo
Beaumont RCSI Cancer Centre, Dublin, Ireland
4 shared publications- Patrick Redmond
Department of General Practice RCSI University of Medicine and Health Sciences Dublin Ireland
4 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by MDPI AG in Preprints.org
Co-Creating Patient Partnerships Within a National Cancer Clinical Trials Network
Structured patient partnership is increasingly recognised in oncology research, yet how trial groups and charities can collaborate to sustain it system-wide is less well described. Cancer Trials Ireland (CTI) established a patient partnership model supported by the Irish Cancer Society (ICS). This paper reviews the model’s development since its inception, aligned with the International Association for Public Participation’s (IAP2) Spectrum of Public Participation. The review draws on institutional records, co-author recollection, organisational learnings, barriers and facilitators, research and strategic outputs, and national and international collaborations. By 2026, 33 patient partners were embedded across all adult disease-specific sub-groups (DSSGs), with patient representation on CTI governance. Facilitators included a funded coordination role, enhanced recruitment, aligned messaging, structural scaffolding, and shared advocacy; barriers included patient diversity, competing commitments, perceptions, and sustainable funding. Patient partners have contributed to investigator-initiated trial concepts and grant applications, and to policy activity, including the National Clinical Trials Oversight Group, the Climate Change Charter, data protection legislation, government general election manifesto advocacy, and public campaigns. Patient-initiated, designed, and led research projects have resulted in international presentations and publications. A structured trials partnership can accelerate and sustain patient partnership beyond individual studies, embedding patient perspectives across trial selection, development, and dissemination, and in shaping policy.
- 20 October 2026
- Published by MDPI AG in Preprints.org
Open AccessCo-Creating Patient Partnerships Within a National Cancer Clinical Trials Network
Structured patient partnership is increasingly recognised in oncology research, yet how trial groups and charities can collaborate to sustain it system-wide is less well described. Cancer Trials Ireland (CTI) established a patient partnership model supported by the Irish Cancer Society (ICS). This paper reviews the model’s development since its inception, aligned with the International Association for Public Participation’s (IAP2) Spectrum of Public Participation. The review draws on institutional records, co-author recollection, organisational learnings, barriers and facilitators, research and strategic outputs, and national and international collaborations. By 2026, 33 patient partners were embedded across all adult disease-specific sub-groups (DSSGs), with patient representation on CTI governance. Facilitators included a funded coordination role, enhanced recruitment, aligned messaging, structural scaffolding, and shared advocacy; barriers included patient diversity, competing commitments, perceptions, and sustainable funding. Patient partners have contributed to investigator-initiated trial concepts and grant applications, and to policy activity, including the National Clinical Trials Oversight Group, the Climate Change Charter, data protection legislation, government general election manifesto advocacy, and public campaigns. Patient-initiated, designed, and led research projects have resulted in international presentations and publications. A structured trials partnership can accelerate and sustain patient partnership beyond individual studies, embedding patient perspectives across trial selection, development, and dissemination, and in shaping policy.
- Open Access
- 26 August 2026
- Published by Wiley in Health Expectations
- Vol. 29 (4)
‘You've Given Me My Voice’—Enhancing Engagement in Exercise Oncology Research: A Patient and Public Involvement Approach to Co‑Designing a Pre‑Radiotherapy Exercise Programme With People Living With Lung Cancer
Background: Emerging evidence suggests exercise may improve radiotherapy efficacy by reducing treatment resistance caused by tumour hypoxia. However, recruitment to exercise oncology studies is low (median 38%), particularly for people with lung cancer. One strategy to address such engagement barriers is by collaborating through Patient and Public Involvement and Engagement (PPIE). Objective: To co‐design an acceptable pre‑radiotherapy exercise programme for people living with lung cancer, incorporating the perspectives and experiences of those affected by the disease. Methods: A PhD researcher collaborated with people impacted by lung cancer and an expert advisory group in a series of meetings and workshops underpinned by the principles of experience‐based co‐design and Boyd's co‐design approach. Workshops were recorded and transcribed verbatim and analysed using reflexive thematic analysis. Findings relating to programme design were deducted into Frequency, Intensity, Time and Type principles, whereas barriers and facilitators were deducted into the five domains of the Practical planning for Implementation and Scale‐up guidelines. Results: Seven attendees accepted workshop invitation, of which three had received a lung cancer diagnosis, and four were family members. Considering design, daily exercise was regarded acceptable for short duration treatment plans, with an optimal duration of 20 min. Exercise intensity must also be personalised and autoregulated. Furthermore, 15 barriers and 40 facilitators were identified, the most pertinent relating to physical activity coach conduct and research design. For example, supervised exercise and developing professional working relationships were considered essential. Conclusions: This project shows how PPIE can effectively inform early research to improve acceptability and presents the first co‑designed pre‑radiotherapy exercise programme for lung cancer. Patient or Public Contribution: PPIE was integral for this project. People diagnosed with lung cancer, along with family members, participated in two co‑design workshops, contributing their perspectives and experiences to shape the development of a pre‑radiotherapy exercise programme. Patient advocates within the advisory group reviewed and refined workshop materials to ensure they were accessible, meaningful, and patient‑friendly. Finally, one co‑design attendee and a patient advocate from the advisory group assisted drafting this manuscript to ensure published findings authentically represent the workshop discussions and the lived experiences shared throughout the project.
- 26 August 2026
- Published by Wiley in Health Expectations
- Vol. 29 (4)
Open Access‘You've Given Me My Voice’—Enhancing Engagement in Exercise Oncology Research: A Patient and Public Involvement Approach to Co‑Designing a Pre‑Radiotherapy Exercise Programme With People Living With Lung Cancer
Background: Emerging evidence suggests exercise may improve radiotherapy efficacy by reducing treatment resistance caused by tumour hypoxia. However, recruitment to exercise oncology studies is low (median 38%), particularly for people with lung cancer. One strategy to address such engagement barriers is by collaborating through Patient and Public Involvement and Engagement (PPIE). Objective: To co‐design an acceptable pre‑radiotherapy exercise programme for people living with lung cancer, incorporating the perspectives and experiences of those affected by the disease. Methods: A PhD researcher collaborated with people impacted by lung cancer and an expert advisory group in a series of meetings and workshops underpinned by the principles of experience‐based co‐design and Boyd's co‐design approach. Workshops were recorded and transcribed verbatim and analysed using reflexive thematic analysis. Findings relating to programme design were deducted into Frequency, Intensity, Time and Type principles, whereas barriers and facilitators were deducted into the five domains of the Practical planning for Implementation and Scale‐up guidelines. Results: Seven attendees accepted workshop invitation, of which three had received a lung cancer diagnosis, and four were family members. Considering design, daily exercise was regarded acceptable for short duration treatment plans, with an optimal duration of 20 min. Exercise intensity must also be personalised and autoregulated. Furthermore, 15 barriers and 40 facilitators were identified, the most pertinent relating to physical activity coach conduct and research design. For example, supervised exercise and developing professional working relationships were considered essential. Conclusions: This project shows how PPIE can effectively inform early research to improve acceptability and presents the first co‑designed pre‑radiotherapy exercise programme for lung cancer. Patient or Public Contribution: PPIE was integral for this project. People diagnosed with lung cancer, along with family members, participated in two co‑design workshops, contributing their perspectives and experiences to shape the development of a pre‑radiotherapy exercise programme. Patient advocates within the advisory group reviewed and refined workshop materials to ensure they were accessible, meaningful, and patient‑friendly. Finally, one co‑design attendee and a patient advocate from the advisory group assisted drafting this manuscript to ensure published findings authentically represent the workshop discussions and the lived experiences shared throughout the project.
- Open Access
- 11 July 2026
- Published by Springer Nature in BMC Health Services Research
- Vol. 26 (1)
Estimating stage-specific lung cancer costs for economic evaluation of LDCT screening in Ireland: a patient-level microsimulation
Lung cancer imposes a significant clinical and economic burden in Ireland, with low five-year survival rates and no national low-dose computed tomography (
- 11 July 2026
- Published by Springer Nature in BMC Health Services Research
- Vol. 26 (1)
Open AccessEstimating stage-specific lung cancer costs for economic evaluation of LDCT screening in Ireland: a patient-level microsimulation
Lung cancer imposes a significant clinical and economic burden in Ireland, with low five-year survival rates and no national low-dose computed tomography (
- Open Access
- 5 December 2025
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 8, 12
Protocol for a Realist Review of mHealth in Lung Cancer Screening: Understanding Mechanisms, Contexts, and Intervention Characteristics for Enhanced Participation
Introduction Lung cancer, the leading cause of cancer death worldwide, is often diagnosed at advanced stages leading to a poorer prognosis. Mobile health (mHealth) interventions, which are healthcare technology utilizing mobile or other wireless technology, promise enhanced early detection by optimising lung cancer screening (LCS) implementation. However, their efficacy across various patient demographics and the underlying mechanisms that influence LCS success remain unclear and underexplored. Aim To explore the efficacy of mHealth interventions in promoting LCS uptake, focusing on patient demographics, intervention characteristics, and the underlying mechanisms and contexts influencing their effectiveness. Methods This realist review will employ an iterative literature search in databases such as PubMed, Scopus, Web of Science, and Embase. Selected studies will be assessed for relevance and rigour, extracting data on mHealth features, patient demographics, and intervention outcomes. Data will be analysed thematically to describe relationships between intervention mechanisms, contexts, and outcomes. Additionally, engagement from key stakeholders, including health experts and patients, will be sought during the synthesis phase. Conclusion This review aims to offer a comprehensive understanding of how and why mHealth interventions can influence LCS uptake and be effective across different patient demographics. These findings will provide insights into optimising mHealth interventions for LCS, potentially leading to earlier detections and improved patient outcomes.
- 5 December 2025
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 8, 12
Open AccessProtocol for a Realist Review of mHealth in Lung Cancer Screening: Understanding Mechanisms, Contexts, and Intervention Characteristics for Enhanced Participation
Introduction Lung cancer, the leading cause of cancer death worldwide, is often diagnosed at advanced stages leading to a poorer prognosis. Mobile health (mHealth) interventions, which are healthcare technology utilizing mobile or other wireless technology, promise enhanced early detection by optimising lung cancer screening (LCS) implementation. However, their efficacy across various patient demographics and the underlying mechanisms that influence LCS success remain unclear and underexplored. Aim To explore the efficacy of mHealth interventions in promoting LCS uptake, focusing on patient demographics, intervention characteristics, and the underlying mechanisms and contexts influencing their effectiveness. Methods This realist review will employ an iterative literature search in databases such as PubMed, Scopus, Web of Science, and Embase. Selected studies will be assessed for relevance and rigour, extracting data on mHealth features, patient demographics, and intervention outcomes. Data will be analysed thematically to describe relationships between intervention mechanisms, contexts, and outcomes. Additionally, engagement from key stakeholders, including health experts and patients, will be sought during the synthesis phase. Conclusion This review aims to offer a comprehensive understanding of how and why mHealth interventions can influence LCS uptake and be effective across different patient demographics. These findings will provide insights into optimising mHealth interventions for LCS, potentially leading to earlier detections and improved patient outcomes.
- Open Access
- 18 November 2025
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 8, 121
Public Preferences for Risk-Stratified Lung Cancer Screening in Ireland: Protocol using a Citizens’ Jury and Stated Preference Methods
Background Lung cancer is a leading cause of cancer mortality in Ireland, accounting for approximately 20% of all cancer deaths, with late-stage presentation contributing to poor survival rates. Low-dose computed tomography screening can reduce lung cancer mortality by 20%, yet eligibility criteria based solely on age and smoking history risk overdiagnosis, false positives, and inequitable access. Risk prediction models such as PLCOm2012 offer improved targeting but require calibration for local populations and integration of public preferences to ensure acceptability and equity in implementation. Aim To inform the design of a risk-stratified lung cancer screening programme for Ireland using a deliberative Citizens’ Jury followed by quantitative preference (DCE) and threshold (TT) elicitation to determine public values and acceptable risk-benefit thresholds. Methods Two citizens’ juries (n=20-24) will explore public values, ethical considerations, and preferences regarding risk-stratified versus population-based screening approaches. A discrete choice experiment (target n=400) will quantify preferences for key screening programme attributes. A threshold technique study (target n = 400) will elicit the individual risk levels at which participants would accept screening using standardised risk communication materials. Expected outcomes The study will produce evidence-based recommendations specifying acceptable risk thresholds for screening eligibility, and preferred programme attributes weighted by relative importance. Conclusion Findings will directly inform the development of shared decision-making tools, guide risk threshold selection for future Irish screening programmes, and provide essential inputs for cost-effectiveness modelling and population impact assessments. Embedding public values and individual preferences from the outset will ensure any future lung cancer screening programme in Ireland is acceptable, equitable, clinically effective, and aligned with population priorities.
- 18 November 2025
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 8, 121
Open AccessPublic Preferences for Risk-Stratified Lung Cancer Screening in Ireland: Protocol using a Citizens’ Jury and Stated Preference Methods
Background Lung cancer is a leading cause of cancer mortality in Ireland, accounting for approximately 20% of all cancer deaths, with late-stage presentation contributing to poor survival rates. Low-dose computed tomography screening can reduce lung cancer mortality by 20%, yet eligibility criteria based solely on age and smoking history risk overdiagnosis, false positives, and inequitable access. Risk prediction models such as PLCOm2012 offer improved targeting but require calibration for local populations and integration of public preferences to ensure acceptability and equity in implementation. Aim To inform the design of a risk-stratified lung cancer screening programme for Ireland using a deliberative Citizens’ Jury followed by quantitative preference (DCE) and threshold (TT) elicitation to determine public values and acceptable risk-benefit thresholds. Methods Two citizens’ juries (n=20-24) will explore public values, ethical considerations, and preferences regarding risk-stratified versus population-based screening approaches. A discrete choice experiment (target n=400) will quantify preferences for key screening programme attributes. A threshold technique study (target n = 400) will elicit the individual risk levels at which participants would accept screening using standardised risk communication materials. Expected outcomes The study will produce evidence-based recommendations specifying acceptable risk thresholds for screening eligibility, and preferred programme attributes weighted by relative importance. Conclusion Findings will directly inform the development of shared decision-making tools, guide risk threshold selection for future Irish screening programmes, and provide essential inputs for cost-effectiveness modelling and population impact assessments. Embedding public values and individual preferences from the outset will ensure any future lung cancer screening programme in Ireland is acceptable, equitable, clinically effective, and aligned with population priorities.
- Open Access
- 28 July 2025
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 6, 64
Co-designing a recruitment strategy for lung cancer screening in high-risk individuals: protocol for a mixed-methods study
Background Lung cancer is a significant cause of cancer-related mortality globally, with early detection through screening critical to improving patient outcomes. However, recruiting high-risk individuals, particularly in deprived populations, for screening remains a considerable challenge. This study aims to co-design a targeted recruitment strategy for lung cancer screening, tailored to the specific needs and experiences of high-risk individuals, in collaboration with a Patient and Public Involvement (PPI) panel and expert stakeholders in Ireland. Methods We will employ a mixed-methods design guided by the Medical Research Council (MRC) framework for developing complex interventions. Our approach will integrate systematic review findings on screening participation interventions, evaluation of the recruitment strategy's feasibility in an Irish context, and the application of behavioural science frameworks. The target population includes individuals aged 55–74 who reside in highly deprived areas and are at high risk of developing lung cancer based on the National Lung Screening Trial criteria, as well as those eligible for our Lung Health Check trial who met equivalent risk thresholds. Conclusion This co-designed recruitment strategy will combine evidence-based research, local context understanding, and stakeholder input to develop a solution that is both scientifically robust and tailored to the target population's needs. This patient-centred approach aims to increase the potential for successful implementation of lung cancer screening programs, thereby improving early detection and patient outcomes.
- 28 July 2025
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 6, 64
Open AccessCo-designing a recruitment strategy for lung cancer screening in high-risk individuals: protocol for a mixed-methods study
Background Lung cancer is a significant cause of cancer-related mortality globally, with early detection through screening critical to improving patient outcomes. However, recruiting high-risk individuals, particularly in deprived populations, for screening remains a considerable challenge. This study aims to co-design a targeted recruitment strategy for lung cancer screening, tailored to the specific needs and experiences of high-risk individuals, in collaboration with a Patient and Public Involvement (PPI) panel and expert stakeholders in Ireland. Methods We will employ a mixed-methods design guided by the Medical Research Council (MRC) framework for developing complex interventions. Our approach will integrate systematic review findings on screening participation interventions, evaluation of the recruitment strategy's feasibility in an Irish context, and the application of behavioural science frameworks. The target population includes individuals aged 55–74 who reside in highly deprived areas and are at high risk of developing lung cancer based on the National Lung Screening Trial criteria, as well as those eligible for our Lung Health Check trial who met equivalent risk thresholds. Conclusion This co-designed recruitment strategy will combine evidence-based research, local context understanding, and stakeholder input to develop a solution that is both scientifically robust and tailored to the target population's needs. This patient-centred approach aims to increase the potential for successful implementation of lung cancer screening programs, thereby improving early detection and patient outcomes.
- Open Access
- 23 July 2025
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 8, 55
Protocol for the economic evaluation of LCS in Ireland: modelling costs, eligibility, and outcomes
Background Lung cancer (LC) is the leading cause of cancer death in Ireland, yet no national screening programme exists. While low-dose computed tomography (LDCT) screening reduces lung cancer mortality by approximately 20% in high-risk populations, its cost-effectiveness in Ireland remains uncertain. Evidence on the economic burden of lung cancer care and the feasibility of screening is needed to support policy decisions. Aim This research programme will evaluate the economic impact of lung cancer care in Ireland and assess the cost-effectiveness of LDCT screening. By integrating screening eligibility modelling, stage-specific cost analysis, and economic evaluation, the study aims to generate evidence to support resource allocation and policy development. Methods The programme consists of three interlinked work packages. First, screening eligibility will be estimated using a dynamic Markov model that integrates demographic data from the Central Statistics Office (CSO), population projections, and smoking history data from Eurobarometer. Second, a stage-specific cost analysis will be conducted using a discrete event simulation (DES) model informed by data from the National Cancer Registry Ireland (NCRI), the Healthcare Pricing Office (HPO), and other healthcare reimbursement sources. Third, a cost-effectiveness analysis will adapt a UK-based LC natural history model (updated ENaBL model 2022) to evaluate alternative screening strategies, incorporating Irish-specific costs, clinical outcomes, and quality-adjusted life-years (QALYs) Results and Implications: This programme will generate evidence to inform the design of a cost-effective LCS programme in Ireland. Findings will guide healthcare planning, optimise screening strategies, and support sustainable policy decisions.
- 23 July 2025
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 8, 55
Open AccessProtocol for the economic evaluation of LCS in Ireland: modelling costs, eligibility, and outcomes
Background Lung cancer (LC) is the leading cause of cancer death in Ireland, yet no national screening programme exists. While low-dose computed tomography (LDCT) screening reduces lung cancer mortality by approximately 20% in high-risk populations, its cost-effectiveness in Ireland remains uncertain. Evidence on the economic burden of lung cancer care and the feasibility of screening is needed to support policy decisions. Aim This research programme will evaluate the economic impact of lung cancer care in Ireland and assess the cost-effectiveness of LDCT screening. By integrating screening eligibility modelling, stage-specific cost analysis, and economic evaluation, the study aims to generate evidence to support resource allocation and policy development. Methods The programme consists of three interlinked work packages. First, screening eligibility will be estimated using a dynamic Markov model that integrates demographic data from the Central Statistics Office (CSO), population projections, and smoking history data from Eurobarometer. Second, a stage-specific cost analysis will be conducted using a discrete event simulation (DES) model informed by data from the National Cancer Registry Ireland (NCRI), the Healthcare Pricing Office (HPO), and other healthcare reimbursement sources. Third, a cost-effectiveness analysis will adapt a UK-based LC natural history model (updated ENaBL model 2022) to evaluate alternative screening strategies, incorporating Irish-specific costs, clinical outcomes, and quality-adjusted life-years (QALYs) Results and Implications: This programme will generate evidence to inform the design of a cost-effective LCS programme in Ireland. Findings will guide healthcare planning, optimise screening strategies, and support sustainable policy decisions.
- Open Access
- 15 April 2025
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 8, 55
Protocol for the economic evaluation of LCS in Ireland: modelling costs, eligibility, and outcomes
Background Lung cancer (LC) is the leading cause of cancer death in Ireland, yet no national screening programme exists. While low-dose computed tomography (LDCT) screening reduces lung cancer mortality by approximately 20% in high-risk populations, its cost-effectiveness in Ireland remains uncertain. Evidence on the economic burden of lung cancer care and the feasibility of screening is needed to support policy decisions. Aim This research programme will evaluate the economic impact of lung cancer care in Ireland and assess the cost-effectiveness of LDCT screening. By integrating screening eligibility modelling, stage-specific cost analysis, and economic evaluation, the study aims to generate evidence to support resource allocation and policy development. Methods The programme consists of three interlinked work packages. First, screening eligibility will be estimated using a dynamic Markov model that integrates demographic data from the Central Statistics Office (CSO), population projections, and smoking history data from Eurobarometer. Second, a stage-specific cost analysis will be conducted using a discrete event simulation (DES) model informed by data from the National Cancer Registry Ireland (NCRI), the Healthcare Pricing Office (HPO), and other healthcare reimbursement sources. Third, a cost-effectiveness analysis will adapt a UK-based LC natural history model (Snowsill, 2018) to evaluate alternative screening strategies, incorporating Irish-specific costs, clinical outcomes, and quality-adjusted life-years (QALYs) Results and Implications: This programme will generate evidence to inform the design of a cost-effective LCS programme in Ireland. Findings will guide healthcare planning, optimise screening strategies, and support sustainable policy decisions.
- 15 April 2025
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 8, 55
Open AccessProtocol for the economic evaluation of LCS in Ireland: modelling costs, eligibility, and outcomes
Background Lung cancer (LC) is the leading cause of cancer death in Ireland, yet no national screening programme exists. While low-dose computed tomography (LDCT) screening reduces lung cancer mortality by approximately 20% in high-risk populations, its cost-effectiveness in Ireland remains uncertain. Evidence on the economic burden of lung cancer care and the feasibility of screening is needed to support policy decisions. Aim This research programme will evaluate the economic impact of lung cancer care in Ireland and assess the cost-effectiveness of LDCT screening. By integrating screening eligibility modelling, stage-specific cost analysis, and economic evaluation, the study aims to generate evidence to support resource allocation and policy development. Methods The programme consists of three interlinked work packages. First, screening eligibility will be estimated using a dynamic Markov model that integrates demographic data from the Central Statistics Office (CSO), population projections, and smoking history data from Eurobarometer. Second, a stage-specific cost analysis will be conducted using a discrete event simulation (DES) model informed by data from the National Cancer Registry Ireland (NCRI), the Healthcare Pricing Office (HPO), and other healthcare reimbursement sources. Third, a cost-effectiveness analysis will adapt a UK-based LC natural history model (Snowsill, 2018) to evaluate alternative screening strategies, incorporating Irish-specific costs, clinical outcomes, and quality-adjusted life-years (QALYs) Results and Implications: This programme will generate evidence to inform the design of a cost-effective LCS programme in Ireland. Findings will guide healthcare planning, optimise screening strategies, and support sustainable policy decisions.
- Open Access
- 10 February 2025
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 8, 29
Protocol for a hybrid systematic review of the barriers and facilitators to implementing lung cancer screening in community settings.
Background Lung cancer remains a leading cause of cancer-related mortality, with early screening using low-dose computed tomography (LDCT) substantially improving survival. However, participation in screening programmes remains low, particularly among underserved populations. This review aims to identify barriers and facilitators to the implementation of lung cancer screening within a behavioural and implementation science framework, to inform strategies that enhance community-based screening uptake. Methods This hybrid systematic review will be conducted in two phases. First, existing systematic reviews on global LDCT-based lung cancer screening recruitment strategies will be identified and screened against eligibility criteria. Second, we will search databases for individual studies not covered by the identified reviews. Studies must focus on community-based lung cancer screening recruitment, with the primary outcome being barriers and facilitators to implementation in these settings. Two independent reviewers will perform screening, selection, bias assessment, and data extraction. A thematic synthesis will be conducted using the Consolidated Framework for Implementation Research (CFIR), with evidence strength assessed using GRADE and CERQual. This protocol adheres to the Joanna Briggs Institute (JBI) Reviewers’ Manual and PRISMA-P guidelines. Conclusion The review will provide comprehensive insights into factors influencing the implementation of lung cancer screening in community settings, aiming to guide improvements in recruitment strategies and increase participation rates. Findings will be disseminated widely to researchers, healthcare practitioners, policymakers, and the public to support the effective implementation of lung cancer screening programmes.
- 10 February 2025
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 8, 29
Open AccessProtocol for a hybrid systematic review of the barriers and facilitators to implementing lung cancer screening in community settings.
Background Lung cancer remains a leading cause of cancer-related mortality, with early screening using low-dose computed tomography (LDCT) substantially improving survival. However, participation in screening programmes remains low, particularly among underserved populations. This review aims to identify barriers and facilitators to the implementation of lung cancer screening within a behavioural and implementation science framework, to inform strategies that enhance community-based screening uptake. Methods This hybrid systematic review will be conducted in two phases. First, existing systematic reviews on global LDCT-based lung cancer screening recruitment strategies will be identified and screened against eligibility criteria. Second, we will search databases for individual studies not covered by the identified reviews. Studies must focus on community-based lung cancer screening recruitment, with the primary outcome being barriers and facilitators to implementation in these settings. Two independent reviewers will perform screening, selection, bias assessment, and data extraction. A thematic synthesis will be conducted using the Consolidated Framework for Implementation Research (CFIR), with evidence strength assessed using GRADE and CERQual. This protocol adheres to the Joanna Briggs Institute (JBI) Reviewers’ Manual and PRISMA-P guidelines. Conclusion The review will provide comprehensive insights into factors influencing the implementation of lung cancer screening in community settings, aiming to guide improvements in recruitment strategies and increase participation rates. Findings will be disseminated widely to researchers, healthcare practitioners, policymakers, and the public to support the effective implementation of lung cancer screening programmes.
- Open Access
- 24 January 2025
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 8, 12
Protocol for a Realist Review of mHealth in Lung Cancer Screening: Understanding Mechanisms, Contexts, and Intervention Characteristics for Enhanced Participation
Introduction Lung cancer, the leading cause of cancer death worldwide, is often diagnosed at advanced stages leading to a poorer prognosis. Mobile health (mHealth) interventions, which are healthcare technology utilizing mobile or other wireless technology, promise enhanced early detection by optimising lung cancer screening (LCS) implementation. However, their efficacy across various patient demographics and the underlying mechanisms that influence LCS success remain unclear and underexplored. Aim To explore the efficacy of mHealth interventions in promoting LCS uptake, focusing on patient demographics, intervention characteristics, and the underlying mechanisms and contexts influencing their effectiveness. Methods This realist review will employ an iterative literature search in databases such as PubMed, Scopus, Web of Science, and Embase. Selected studies will be assessed for relevance and rigour, extracting data on mHealth features, patient demographics, and intervention outcomes. Data will be analysed thematically to describe relationships between intervention mechanisms, contexts, and outcomes. Additionally, engagement from key stakeholders, including health experts and patients, will be sought during the synthesis phase. Conclusion This review aims to offer a comprehensive understanding of how and why mHealth interventions can influence LCS uptake and be effective across different patient demographics. These findings will provide insights into optimising mHealth interventions for LCS, potentially leading to earlier detections and improved patient outcomes.
- 24 January 2025
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 8, 12
Open AccessProtocol for a Realist Review of mHealth in Lung Cancer Screening: Understanding Mechanisms, Contexts, and Intervention Characteristics for Enhanced Participation
Introduction Lung cancer, the leading cause of cancer death worldwide, is often diagnosed at advanced stages leading to a poorer prognosis. Mobile health (mHealth) interventions, which are healthcare technology utilizing mobile or other wireless technology, promise enhanced early detection by optimising lung cancer screening (LCS) implementation. However, their efficacy across various patient demographics and the underlying mechanisms that influence LCS success remain unclear and underexplored. Aim To explore the efficacy of mHealth interventions in promoting LCS uptake, focusing on patient demographics, intervention characteristics, and the underlying mechanisms and contexts influencing their effectiveness. Methods This realist review will employ an iterative literature search in databases such as PubMed, Scopus, Web of Science, and Embase. Selected studies will be assessed for relevance and rigour, extracting data on mHealth features, patient demographics, and intervention outcomes. Data will be analysed thematically to describe relationships between intervention mechanisms, contexts, and outcomes. Additionally, engagement from key stakeholders, including health experts and patients, will be sought during the synthesis phase. Conclusion This review aims to offer a comprehensive understanding of how and why mHealth interventions can influence LCS uptake and be effective across different patient demographics. These findings will provide insights into optimising mHealth interventions for LCS, potentially leading to earlier detections and improved patient outcomes.